Masitinib reduces time to disability progression for patients with PPMS, non-active SPMS

Treatment with masitinib, a first-in-class tyrosine kinase inhibitor, led to significant improvement in Expanded Disability Scale Status, or EDSS, for…

Masitinib reduces time to disability progression for patients with PPMS, non-active SPMS

https://www.healio.com/~/media/images/fscss/i3wyanokecdncom/healio_safe_image.png
Treatment with masitinib, a first-in-class tyrosine kinase inhibitor, led to significant improvement in Expanded Disability Scale Status, or EDSS, for patients with MS, according to findings presented at MSVirtual2020. “We know, in MS, that both adaptive immunity and innate immunity play a role. Many data suggest that microglia and mast cells are associated with the pathophysiology of MS,
#NDIS #shufflernews #NDISSoletrader

www.shufflernews.com

Another NDIS Sole Trader Initiative

Unfunded, unsponsored and UNREAL

This post was originally published on this site NDIS News Feed Rss.app https://rss.app/feeds/a9qJtTN0lY5uESwx.xml

Be Part of the Family !

Come in, share your details and get involved !

You have Successfully Subscribed!